It's a subdued start to trading with tariff talk dampening US markets. Pharmaceutical and Energy stocks are the unlucky ...

SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Interim Results from FDA-Funded Study Reinforces HyBryte's Rapid Response and Strong Safety Profile PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix ...

About linperlisib Linperlisib is a next-generation highly selective PI3Kδ inhibitor with a well-tolerated and differentiated safety profile as indicated from clinical trials in follicular lymphoma (FL ...

These findings were suggestive of T-cell lymphoma. Serologies for tuberculosis ... We diagnosed folliculotropic mycosis fungoides with early large-cell transformation (stage IIIB). We referred the ...

It’s more common in older adults, people with weakened immune systems, and people with primary CNS lymphoma. There are two main types of lymphocytes, called B cells and T cells. But the kind ...

It doesn’t make ... of mycosis fungoides or Sézary syndrome; — Oxlumo, for the treatment of hyperoxaluria type 1; — Epkinly, for relapsed or refractory diffuse large B-cell lymphoma ...